Director or Officer Departures, Elections, Appointments, and Compensation Arrangements

Business Context and Reporting Period

This Form 8-K was filed by Coeptis Therapeutics Holdings, Inc. on May 17, 2023, under Items 5.02, 8.01, and 9.01. The filing reports a chief financial officer transition and related employment arrangements. The request metadata identifies Z Squared Inc., but the filing names Coeptis Therapeutics Holdings, Inc. as the registrant.

Key Financial Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial performance metrics.

Material Changes Versus the Prior Comparable Period

  • Christine Sheehy stepped down as Chief Financial Officer effective immediately on May 17, 2023.
  • Ms. Sheehy remained with the Company as Vice President of Compliance and Corporate Secretary.
  • Brian Cogley, age 37, was appointed Chief Financial Officer effective immediately.

Guidance, Outlook, Risks, and Unusual Items

  • Mr. Cogley has more than 15 years of accounting and finance experience, including roles at KPMG, CFGI, NexTier Bank, Calgon Carbon, and TriState Capital Bank.
  • His offer letter provides for an annual base salary of $200,000, eligibility for an annual discretionary bonus, participation in the Company’s stock incentive plan with the number of options to be determined, and standard employee benefits.
  • Mr. Cogley’s employment is at will.
  • The filing states that there are no undisclosed appointment arrangements, family relationships requiring disclosure, or reportable related-party interests under Item 404(a) of Regulation S-K.
  • No financial guidance or specific business outlook was provided.

Important Facts for Investors to Verify

  • Confirm the registrant identity, as the filing identifies Coeptis Therapeutics Holdings, Inc., while the request metadata identifies Z Squared Inc.
  • Review the Company’s subsequent filings for the final terms and number of stock options granted to Mr. Cogley.
  • Assess whether the CFO transition affects financial reporting, compliance, internal controls, or the timing of future filings.
  • Review Exhibit 99.1, the May 17, 2023 press release, for any additional management commentary.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.